胶质瘤中血管生成拟态的研究进展

doi:10.3760/cma.j.issn.1673-422X.2014.12.008

摘要/Abstract

摘要： 血管生成拟态（VM）是一种肿瘤细胞通过自身变形并模拟产生血管样通道而达到自身血液供应的方式。胶质瘤中VM的形成与胶质瘤干细胞关系密切，另外一些分子如微小RNA（miRNA）、上皮细胞激酶（EphA2）、血管内皮钙黏蛋白（VEcadherin）、转化生长因子β（TGFβ）、血管内皮细胞生长因子受体2（VEGFR2）、凝集素1（Gal1）等在胶质瘤VM形成过程中也发挥重要作用。VM与胶质瘤患者的预后不良及其抗血管药物疗效不佳密切相关，所以针对VM形成机制、预后影响以及临床意义的研究将为胶质瘤的早期诊断和治疗提供新思路和可能的新靶点。

关键词: 神经胶质瘤, 血管生成拟态

Abstract: Vasculogenic mimicry (VM) is a pattern of neoplasm cells, which achieve their blood supplements through deformation and simulating capillary channels. Cumulative studies show that the formation of VM in glioma have a close relation with the glioma stem cells. In addition, some molecules such as microRNA, epithelial cell kinaseA2, vascular endothelial cadherin, transforming growth factorβ, vascular endothelial growth factor receptor2 and galectin1 play important roles in the forming process of vasculogenic mimicry. Recently, it is found that VM is associated with the poor prognosis of patients with glioma and anti angiogenesis drug efficacy. So the research on VM about the discovery, formation mechanism, prognostic impact and the clinical significance will provide an opportunity for diagnosis and therapy of glioma in early stage.

Key words: Glioma, Vasculogenic mimicry

邓君, 郭宇宏, 郭庚. 胶质瘤中血管生成拟态的研究进展[J]. 国际肿瘤学杂志, 2014, 41(12): 902-905.

DENG Jun, GUO Yu-Hong, GUO Geng. Research advance on vasculogenic mimicry in glioma[J]. Journal of International Oncology, 2014, 41(12): 902-905.

参考文献

［1］ Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system［J］. Acta Neuropathol, 2007, 114(2): 97109. ［2］ Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma［J］. Clin Cancer Res, 2007, 13(4): 12531259. ［3］ Kreisl TN, Kim L, Moore K, et al. Phase Ⅱ trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma［J］. J Clin Oncol, 2009, 27(5): 740745. ［4］ Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry［J］. Am J Pathol, 1999, 155(3): 739752. ［5］ Fan YZ, Sun W. Molecular regulation of vasculogenic mimicry in tumors and potential tumortarget therapy［J］. World J Gastrointest Surg, 2010, 2(4): 117127. ［6］ Paulis YW, Soetekouw PM, Verheul HM, et al. Signalling pathways in vasculogenic mimicry［J］. Biochim Biophys Acta, 2010, 1806(1): 1828. ［7］ Zhang Y, Sun B, Zhao X, et al. Clinical significances and prognostic value of cancer stemlike cells markers and vasculogenic mimicry in renal cell carcinoma［J］. J Surg Oncol, 2013, 108(6): 414419. ［8］ Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? ［J］. J Histochem Cytochem, 2005, 53(8): 9971002. ［9］ El Hallani S, Boisselier B, Peglion F, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry［J］. Brain, 2010, 133(Pt 4): 973982. ［10］ Chen Y, Jing Z, Luo C, et al. Vasculogenic mimicrypotential target for glioblastoma therapy: an in vitro and in vivo study［J］. Med Oncol, 2012, 29(1): 324331. ［11］ Liu Z, Li Y, Zhao W, et al. Demonstration of vasculogenic mimicry in astrocytomas and effects of Endostar on U251 cells［J］. Pathol Res Pract, 2011, 207(10): 645651. ［12］ Dong J, Zhao Y, Huang Q, et al. Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation［J］. Stem Cell Rev, 2011, 7(1): 141152. ［13］ Scully S, Francescone R, Faibish M, et al. Transdifferentiation of glioblastoma stemlike cells into mural cells drives vasculogenic mimicry in glioblastomas［J］. J Neurosci, 2012, 32(37): 1295012960. ［14］ Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact［J］. J Clin Oncol, 2009, 27(34): 58485856. ［15］ Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2)［J］. Cancer Res, 2001, 61(8): 32503255. ［16］ Wu N, Zhao X, Liu M, et al. Role of microRNA26b in glioma development and its mediated regulation on EphA2［J］. PLoS One, 2011, 6(1): e16264. ［17］ Krichevsky AM, Sonntag KC, Isacson O, et al. Specific microRNAs modulate embryonic stem cellderived neurogenesis［J］. Stem Cells, 2006, 24(4): 857864. ［18］ Dong B, Mu L, Qin X, et al. Stathmin expression in gliomaderived microvascular endothelial cells: a novel therapeutic target［J］. Oncol Rep, 2012, 27(3): 714718. ［19］ Song Y, Mu L, Han X, et al. MicroRNA9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression［J］. J Neurooncol, 2013, 115(3): 381390. ［20］ Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functional significance of VEcadherin in aggressive human melanoma cells: role in vasculogenic mimicry［J］. Proc Natl Acad Sci U S A, 2001, 98(14): 80188023. ［21］ Hess AR, Margaryan NV, Seftor EA, et al. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors［J］. Dev Dyn, 2007, 236(12): 32833296. ［22］ Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase2, and membrane type1matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma［J］. Cancer Res, 2001, 61(17): 63226327. ［23］ Mao XG, Xue XY, Wang L, et al. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia［J］. Neuro Oncol, 2013, 15(7): 865879. ［24］ Ling G, Wang S, Song Z, et al. Transforming growth factorbeta is required for vasculogenic mimicry formation in glioma cell line U251MG［J］. Cancer Biol Ther, 2011, 12(11): 978988. ［25］ Serwe A, Rudolph K, Anke T, et al. Inhibition of TGFbeta signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol［J］. Invest New Drugs, 2012, 30(3): 898915. ［26］ Francescone R, Scully S, Bentley B, et al. Glioblastomaderived tumor cells induce vasculogenic mimicry through VEGFR2 protein activation［J］. J Biol Chem, 2012, 287(29): 2482124831. ［27］ Yao X, Ping Y, Liu Y, et al. Vascular endothelial growth factor receptor 2 (VEGFR2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stemlike cells［J］. PLoS One, 2013, 8(3): e57188. ［28］ Foltz G, Ryu GY, Yoon JG, et al. Genomewide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma［J］. Cancer Res, 2006, 66(13): 66656674. ［29］ Le Mercier M, Fortin S, Mathieu V, et al. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression［J］. Neoplasia, 2009, 11(5): 485496. ［30］ Liu XM, Zhang QP, Mu YG, et al. Clinical significance of vasculogenic mimicry in human gliomas［J］. J Neurooncol, 2011, 105(2): 173179. ［31］ Wang SY, Ke YQ, Lu GH, et al. Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma［J］. J Neurooncol, 2013, 112(3): 339345. ［32］ Qu B, Guo L, Ma J, et al. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system［J］. Med Hypotheses, 2010, 74(2): 360361. ［33］ Xu Y, Li Q, Li XY, et al. Shortterm antivascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis［J］. J Exp Clin Cancer Res, 2012, 31: 16. ［34］郭世文, 张熙, 尉春艳. Alphastatin多肽对胶质瘤血管生成拟态的抑制作用及其相关机制［J］. 重庆医学, 2011, 40(21): 20842086.

[1]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[2]	肖楠, 孙鹏飞. 氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361.
[3]	孔春禹, 孙鹏飞. SLC7A11与胶质瘤[J]. 国际肿瘤学杂志, 2022, 49(10): 604-607.
[4]	郭世豪, 任叶青, 郭庚. 脑胶质瘤血管生成拟态分子机制[J]. 国际肿瘤学杂志, 2021, 48(6): 362-365.
[5]	王宪伟, 史美燕, 王凤芹, 齐福, 王朝喆, 周飞. TSA上调miR-4298靶向抑制PADI4表达在诱导U251细胞凋亡中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 193-199.
[6]	张雯, 胡伟国, 宋启斌. 3D-ASL与DCE-MRI在脑胶质瘤复发与放射性脑坏死鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(10): 631-634.
[7]	赵聪选, 于韬. 胶质瘤相关基因的挖掘及预测[J]. 国际肿瘤学杂志, 2020, 47(5): 293-296.
[8]	南阳, 钟跃. 长非编码RNA在神经胶质瘤研究中的新进展[J]. 国际肿瘤学杂志, 2020, 47(2): 98-102.
[9]	张雯, 宋启斌, 胡伟国. 多模态磁共振成像在脑胶质瘤中的临床应用[J]. 国际肿瘤学杂志, 2020, 47(11): 686-690.
[10]	陈亮, 秦军, 雷军荣, 刘俊, 王璐. miR-1254通过靶向CSF-1抑制胶质瘤细胞的增殖和侵袭能力[J]. 国际肿瘤学杂志, 2020, 47(10): 577-584.
[11]	张千慧, 张洋, 宿伟鹏, 张宋安, 刘攀, 赵化荣. LSD1、MGMT和Ki-67在高级别胶质瘤中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2019, 46(9): 519-525.
[12]	衣琳, 邱实. 紫草素抗胶质瘤效应及其作用机制[J]. 国际肿瘤学杂志, 2019, 46(8): 489-491.
[13]	于学娟, 安宏伟, 孙亚梅, 姜政, 张学海, 杨文敬, 张伟. MMP2、TIMP2、Ki-67、P53在胶质瘤组织中的表达及意义 [J]. 国际肿瘤学杂志, 2019, 46(12): 718-722.
[14]	卢迪,张钧栋,郭庚,王小刚. 干扰素通路中的关键分子诱导脑胶质瘤细胞凋亡的机制[J]. 国际肿瘤学杂志, 2018, 45(7): 432-435.
[15]	张园园，朱淑霞. 微小RNA-495在神经胶质瘤中的作用机制[J]. 国际肿瘤学杂志, 2018, 45(6): 362-364.